|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ study of NGR-hTNF,a selective vascular targeting agent,in patients with metastatic colorectal cancer after failure of standard therapy显示文摘 | Santoro A Rimassa L Sobrero AF | 2010 | Eur J Cancer2010，46，15： | 1 |
| 2 | Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy显示文摘 | Carnaghi C Troneoni MC Rimassa L | 2007 | Nuclear medicine review Central & Eastern Europe2007，10，1： | 1 |
| 3 | Tivantinib for second- line treatment of advanced hepatocellular carcinoma : randomised, placebo-controlled phase 2 study显示文摘 | Santoro A Rimassa L Borbath I | 2013 | Lancet Oncol2013，14，1： | 1 |
| 4 | Sorafenib therapy in advanced hepatocellular carcinoma:the SHARP trial显示文摘 | Rimassa L Santoro A | 2009 | Expert Rev Anticancer Ther2009，9，6： | 1 |
| 5 | The efficacy of hybrid chemotherapy with intravenous oxaliplatin and fo- linic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase 11 study 显示文摘 | Camaghi C Santoro A Rimassa L et a/ | 2007 | 1nvest New Drugs2007，25，5： | 1 |
| 6 | 5-Fluorouracil,dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 显示文摘 | Rimassa L Carnaghi C | 1998 | Cancer1998，83，： | 1 |
| 7 | An exploratory biomarkerstudy in metastatic tumors from colorectal cancer patients treatedwith bevacizumab显示文摘 | Sclafani F Rimassa L Colombo P | 2014 | Int J Biol Markers2014，10，： | 1 |
| 8 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma:A randomised,placebo-controlled phase 2 study显示文摘 | Santoro A Rimassa L Borbath I | 2013 | Lancet Oncol2013，14，1： | 1 |
| 9 | Irinotecan and raltitrexed: an active combination in advanced colorectal cancer显示文摘 | Carnaghi C Rimassa L Garassino I | 2002 | Ann Oncol2002，13，9： | 1 |
| 10 | Sorafenib in patientswith Child-Pugh class A and B advanced hepatocellular carcino-ma: a prospective feasibility analysis 显示文摘 | Pressiani T Boni C Rimassa L | 2013 | Annals of oncology2013，24，2： | 1 |
| 11 | Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial显示文摘 | Rimassa L Santoro A | 2009 | Expert Rev Anticancer Ther2009，9，6： | 1 |
| 12 | Clinical signficance of neuroendocrine phenotype in non-small cell lung cancer显示文摘 | Carnaghi C Rimassa L Garassino I | 2001 | Ann Oncol2001，12，2： | 1 |
| 13 | Phase II study of NGR-hT-NF,a selective vascular targeting agent,in patients with metastaticcolorectal cancer after failure of standard therapy显示文摘 | Santoro A Rimassa L Sobrero AF | 2010 | Eur J Cancer2010，46，15： | 1 |
| 14 | A phase II randomized dose escalation trial of sorafenib in patients with advanced hepato- cellular carcinoma显示文摘 | Rimassa L Pressiani T Boni C | 2013 | Oncologist2013，18，4： | 1 |
| 15 | A modular serpen- tine rescue robot with climbling ability 显示文摘 | RIMASSA L ZOPPI M MOLFINO R | 2009 | Industrial Robot2009，36，4： | 1 |
| 16 | Sorafenib in patients with Child-Pugh class A and B advanced hepatocellu- lar carcinoma:a prospective feasibility analysis 显示文摘 | PRESSIANI T BONI C RIMASSA L | 2013 | Ann On- col2013，24，2： | 1 |
| 17 | Tivantinib for second- line treatment of advanced hepatocellular earcinoma: a random- ized,placebo-controlled phase 2 study显示文摘 | Santoro A Rimassa L Borbath I | 2013 | Lancet Oncol2013，14，1： | 1 |
| 18 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: arandomised, placebo-controlled phase 2 study 显示文摘 | Santoro A Rimassa L Borbath I | 2013 | LancetOncol2013，14，1： | 1 |
| 19 | Tivantinib for second - line treatment of advanced hepatocellular carcinoma: A randomised, placebo- controlled phase 2 study 显示文摘 | Santoro A Rimassa L Borbath I | 2013 | Lancet Oncol2013，14，1： | 1 |
| 20 | Molecular determin-ants of outcome in sorafenib-treated patients with hepatocellular carcinoma显示文摘 | Personeni N Rimassa L Pressiani T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员